SEARCH:   Advanced

Blood, Vol. 111, Issue 3, 1584-1593, February 1, 2008 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia Blood Saddler et al. 111: 1584 Supplemental materials for: Saddler et al Files in this Data Supplement: Table S1. Detailed compilation of 106 CLL cases and associated biomarkers (XLS, 36.5 KB) Table S2. IC50 values for MI63 and Nutlin3 kill for 106 CLL patients (XLS, 21 KB) Figure S1. Prior therapies do not affect CLL cell kill by MDM2 inhibitors (JPG, 54.5 KB) - One hundred and six CLL samples (85 previously untreated and 21 previously treated) were enriched for CD19+ cells through negative selection and incubated for 36h with various concentrations of either MI-63 or Nutlin3. Samples were prepared for annexin-V and PI staining and analyzed by flow cytometry, and the residual live and non-apoptotic cell fraction was calculated for each concentration through comparison with the untreated control incubation. (A) MI-63 assay result, composites. Red: pretreated CLL cases composite; black: untreated CLL cases, composite. (B) Nutlin3 assay results. Red: pretreated CLL cases, composite; black: untreated CLL cases, composite. Standard deviations are indicated by vertical black bars. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020